Inactive Instrument

All News Avacta Group Plc London S.E.

Equities

End-of-day quote London S.E. Other stock markets
- ^GBX	-

05-07	AstraZeneca target raised; Antofagasta lowered	AN
05-01	Avacta picks Christina Coughlin to replace long-serving CEO	AN

AstraZeneca target raised; Antofagasta lowered	05-07	AN
Avacta Group plc - Christina Coughlin, MD, PhD, appointed Chief Executive Officer of Avacta Group	05-01	AQ
Avacta picks Christina Coughlin to replace long-serving CEO	05-01	AN
EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down	04-30	AN
Avacta Group CEO Steps Down; Successor Appointed	04-30	MT
Transcript : Avacta Group Plc, 2023 Earnings Call, Apr 30, 2024	04-30
Avacta : Results for the Year Ended 31 December 2023	04-30	PU
Avacta : Preliminary Results for the Year Ended 31 December 2023	04-30	PU
Avacta : Christina Coughlin, MD, PhD, appointed Chief Executive Officer of Avacta Group	04-30	PU
Avacta Group Plc Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
Avacta Group plc Announces Chief Executive Officer Changes	04-30	CI
Avacta : R&D Spotlight series – Episode 2	04-25	PU
Avacta Group plc - Block Listing Application to AIM	04-24	AQ
Avacta Group plc - Notice of Results	04-24	AQ
First Tin updates Tellerhauser estimates	04-22	AN
Transcript : Avacta Group Plc - Special Call	04-10
Avacta Therapeutics Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 at the AACR Annual Meeting Demonstrating Clinical Proof-of-Concept Showing Multiple Patient Responses	04-10	AQ
Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting	04-09	CI
Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update	04-05	GL
Avacta : Glossary	04-05	PU

No results for this search